참여 물질
| 역할 | 이름 | HCID | 투입량 |
|---|
| 반응물 | 4-Piperidinecarboxamide | HCID 3772 | — |
| 반응물 | 3-Bromoanisole | HCID 16971 | — |
| 시약 | Lithium Hexamethyldisilazide | HCID 2733832 | — |
| 촉매 | Palladium (II) acetate | HCID 4144353 | — |
| 촉매 | 2,8,9-Triisobutyl-2,5,8,9-tetraaza-1-phosphabicyclo(3.3.3)undecane | HCID 4571243 | — |
| 용매 | Toluene | HCID 1140 | — |
| 생성물 | 1-(3-Methoxyphenyl)piperidine-4-carboxamide | HCID 10609747 | 0% |
반응 단계
piperidine-4-carboxamide (0.411 g, 3.21 mmol); 1-bromo-3-methoxybenzene (0.339 mL, 2.67 mmol) and diacetoxypalladium (0.120 g, 0.53 mmol) were thoroughly placed under an inert atmoshere. To this was added 2,8,9-triisobutyl-2,5,8,9-tetraaza-1-phosphabicyclo[3.3.3]undecane (0.037 g, 0.11 mmol); LITHIUM BIS(TRIMETHYLSILYL)AMIDE (6.15 mL, 6.15 mmol) and toluene (10 mL). The resultant mixture was stirred at 100 °C overnight. No sign of reaction by LCMS overnight. Abandoned
출처 및 근거
| 출처 데이터셋 | 750 AstraZeneca ELN dataset |
|---|
| ORD ID | ord-c91f5415f0604adda8f4b73dd97ab0f8 |
|---|
| 출처 메모 | 750 AstraZeneca ELN dataset |
|---|
